{"title":"英国骨髓瘤研究联盟风险简介对接受美法仑、泼尼松和硼替佐米方案的不符合移植条件的多发性骨髓瘤患者预后影响的校正：JCOG1105的补充分析。","authors":"","doi":"10.1002/hon.3226","DOIUrl":null,"url":null,"abstract":"<p>Suzuki T, Maruyama D, Machida R, et al. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105. <i>Hematol Oncol.</i> 2023;41(3):590–593. https://doi.org/10.1002/hon.3103.</p><p>Subsequent to the publication of above article, the authors noted that the serum β2MG data (median level and unit) in Table 1 were incorrect. The correct median β2MG level is 3.1 (range, 1.4–14.3). The correct unit for β2MG is mg/L. This correction does not change the interpretation of the data or the overall conclusions of the study. The corrected Table 1 is shown below. The authors wish to apologize for any inconvenience caused.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3226","citationCount":"0","resultStr":"{\"title\":\"Correction to Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105\",\"authors\":\"\",\"doi\":\"10.1002/hon.3226\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Suzuki T, Maruyama D, Machida R, et al. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105. <i>Hematol Oncol.</i> 2023;41(3):590–593. https://doi.org/10.1002/hon.3103.</p><p>Subsequent to the publication of above article, the authors noted that the serum β2MG data (median level and unit) in Table 1 were incorrect. The correct median β2MG level is 3.1 (range, 1.4–14.3). The correct unit for β2MG is mg/L. This correction does not change the interpretation of the data or the overall conclusions of the study. The corrected Table 1 is shown below. The authors wish to apologize for any inconvenience caused.</p>\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2023-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3226\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.3226\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.3226","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Correction to Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105
Suzuki T, Maruyama D, Machida R, et al. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105. Hematol Oncol. 2023;41(3):590–593. https://doi.org/10.1002/hon.3103.
Subsequent to the publication of above article, the authors noted that the serum β2MG data (median level and unit) in Table 1 were incorrect. The correct median β2MG level is 3.1 (range, 1.4–14.3). The correct unit for β2MG is mg/L. This correction does not change the interpretation of the data or the overall conclusions of the study. The corrected Table 1 is shown below. The authors wish to apologize for any inconvenience caused.
期刊介绍：
Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:
-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders
-Diagnostic investigations, including imaging and laboratory assays
-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases
-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies
-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.
Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
